Masked immunotherapy VIR-5500 shows early promise against prostate cancer
A masked T-cell engager called VIR-5500 demonstrated early promise in an ongoing advanced prostate cancer trial, with 82% of high-dose patients seeing PSA reductions and about half showing tumor shrinkage; masking aims to reduce inflammatory toxicity and enable safer, slower activation, though results are preliminary and not yet peer-reviewed.